JP2015510892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510892A5 JP2015510892A5 JP2015500602A JP2015500602A JP2015510892A5 JP 2015510892 A5 JP2015510892 A5 JP 2015510892A5 JP 2015500602 A JP2015500602 A JP 2015500602A JP 2015500602 A JP2015500602 A JP 2015500602A JP 2015510892 A5 JP2015510892 A5 JP 2015510892A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- nrc
- haloalkyl
- halogen
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 150000001356 alkyl thiols Chemical class 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 201000005991 hyperphosphatemia Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010051246 Photodermatosis Diseases 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 206010048214 Xanthoma Diseases 0.000 claims 1
- 206010048215 Xanthomatosis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- -1 methyl halide Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 230000008845 photoaging Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612051P | 2012-03-16 | 2012-03-16 | |
| US61/612,051 | 2012-03-16 | ||
| PCT/US2013/031242 WO2013138565A1 (en) | 2012-03-16 | 2013-03-14 | Liver x receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017048432A Division JP2017128588A (ja) | 2012-03-16 | 2017-03-14 | 肝臓ｘレセプターモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510892A JP2015510892A (ja) | 2015-04-13 |
| JP2015510892A5 true JP2015510892A5 (https=) | 2016-04-28 |
| JP6114814B2 JP6114814B2 (ja) | 2017-04-12 |
Family
ID=47997957
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500602A Expired - Fee Related JP6114814B2 (ja) | 2012-03-16 | 2013-03-14 | 肝臓ｘレセプターモジュレーター |
| JP2017048432A Pending JP2017128588A (ja) | 2012-03-16 | 2017-03-14 | 肝臓ｘレセプターモジュレーター |
| JP2018172260A Pending JP2019023196A (ja) | 2012-03-16 | 2018-09-14 | 肝臓ｘレセプターモジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017048432A Pending JP2017128588A (ja) | 2012-03-16 | 2017-03-14 | 肝臓ｘレセプターモジュレーター |
| JP2018172260A Pending JP2019023196A (ja) | 2012-03-16 | 2018-09-14 | 肝臓ｘレセプターモジュレーター |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9006244B2 (https=) |
| EP (1) | EP2825541B1 (https=) |
| JP (3) | JP6114814B2 (https=) |
| KR (1) | KR102069912B1 (https=) |
| CN (1) | CN104203951B (https=) |
| AU (1) | AU2013232066B2 (https=) |
| CA (1) | CA2866218C (https=) |
| CY (1) | CY1118318T1 (https=) |
| DK (1) | DK2825541T3 (https=) |
| EA (1) | EA026907B1 (https=) |
| ES (1) | ES2598653T3 (https=) |
| HR (1) | HRP20161196T1 (https=) |
| HU (1) | HUE029402T2 (https=) |
| IL (1) | IL234265B (https=) |
| IN (1) | IN2014DN07636A (https=) |
| LT (1) | LT2825541T (https=) |
| ME (1) | ME02534B (https=) |
| MX (1) | MX354818B (https=) |
| NZ (1) | NZ629122A (https=) |
| PL (1) | PL2825541T3 (https=) |
| PT (1) | PT2825541T (https=) |
| RS (1) | RS55166B1 (https=) |
| SG (1) | SG11201405328SA (https=) |
| SI (1) | SI2825541T1 (https=) |
| SM (1) | SMT201600374B (https=) |
| WO (1) | WO2013138565A1 (https=) |
| ZA (1) | ZA201406326B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2607113T3 (es) * | 2012-03-16 | 2017-03-29 | Vitae Pharmaceuticals, Inc. | Moduladores de los receptores X del hígado |
| SI2825541T1 (sl) * | 2012-03-16 | 2016-10-28 | Vitae Pharmaceuticals, Inc. | Modulatorji jetrnega receptorja X |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| WO2015195922A1 (en) * | 2014-06-19 | 2015-12-23 | Vitae Pharmaceuticals, Inc. | Compounds for use in treating acute coronary syndrome and related conditions |
| EA031480B1 (ru) * | 2014-08-07 | 2019-01-31 | Вайтаи Фармасьютиклз, Инк. | Модуляторы x-рецепторов печени |
| WO2016100619A2 (en) * | 2014-12-17 | 2016-06-23 | Rgenix, Inc. | Treatment and diagnosis of cancer |
| CN105017262B (zh) * | 2015-07-07 | 2017-05-03 | 广东也乐新材料制造有限公司 | 一种醛基取代多环杂芳烃化合物的合成方法 |
| CN105288658B (zh) * | 2015-10-30 | 2018-08-28 | 中国人民解放军第三军医大学 | miR-18a-5p抑制剂在制备防治骨质疏松药物中的应用 |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4748247A (en) | 1986-10-21 | 1988-05-31 | American Home Products Corporation | 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists |
| EP0511993A1 (en) | 1990-01-22 | 1992-11-11 | E.I. Du Pont De Nemours And Company | Herbicidal sulfonylureas |
| EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| ES2236702T3 (es) | 1993-12-23 | 2005-07-16 | Eli Lilly And Company | Inhibidores de la proteina quinasa c. |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| WO1996012721A1 (en) | 1994-10-20 | 1996-05-02 | American Home Products Corporation | Indole derivatives useful as serotonergic agents |
| EP0912513A1 (en) | 1996-06-28 | 1999-05-06 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| EP0912182A4 (en) | 1996-06-28 | 1999-12-29 | Merck & Co Inc | FIBRINOGEN RECEPTOR ANTAGONISTIC PRODRUGS |
| US5854245A (en) | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| EP0912175A4 (en) | 1996-06-28 | 1999-09-08 | Merck & Co Inc | FIBRINOGENIC RECEPTOR ANTAGONISTS |
| US6177440B1 (en) | 1996-10-30 | 2001-01-23 | Eli Lilly And Company | Substituted tricyclics |
| FR2761070B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
| FR2761073B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
| DE19802235A1 (de) | 1998-01-22 | 1999-07-29 | Bayer Ag | Mit tricyclischen Indolen substituierte Oxazolidinone |
| IL129484A0 (en) | 1998-04-17 | 2000-02-29 | Lilly Co Eli | Substituted tricyclics |
| BR0010308A (pt) | 1999-05-06 | 2002-01-08 | Neurogen Corp | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa e para alterar a atividade da transdução de sinal dos receptores de gabaa, e, composição farmacêutica embalada |
| US7037916B2 (en) | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
| IT1313593B1 (it) | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo. |
| WO2001030331A2 (en) | 1999-10-22 | 2001-05-03 | Eli Lilly And Company | Therapeutic compositions including protein kinase c inhibitors |
| WO2001049288A1 (en) | 2000-01-06 | 2001-07-12 | Merck Frosst Canada & Co. | Novel compounds and compositions as protease inhibitors |
| MXPA03000906A (es) | 2000-07-31 | 2005-02-24 | Hoffmann La Roche | Derivados de piperazina. |
| HUP0303316A2 (hu) | 2000-12-20 | 2004-01-28 | Bristol-Myers Squibb Pharma Company | Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| FR2829766A1 (fr) | 2001-09-14 | 2003-03-21 | Lipha | Derives d'oxamates comportant un heterocycle azote diversement substitue |
| BR0215288A (pt) | 2001-12-21 | 2004-12-21 | King Phamaceuticals Res & Dev | Composto, sais farmaceuticamente aceitáveis do mesmo, e, métodos para identificar células tumorais ricas em receptores de p2x7, purinérgicos em um mamìfero, para tratar de uma condição médica em um mamìfero, e para induzir a apoptose em células neoplásticas em um paciente |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| DE10320780A1 (de) | 2003-05-09 | 2005-01-20 | Bayer Healthcare Ag | Heterocyclyl-substituierte Dihydrochinazoline |
| ES2564804T3 (es) | 2004-02-12 | 2016-03-29 | Mitsubishi Tanabe Pharma Corporation | Compuesto de indazol y uso farmacéutico del mismo |
| JP2007532506A (ja) | 2004-04-08 | 2007-11-15 | ノバルティス アクチエンゲゼルシャフト | 自己免疫疾患および拒絶反応の処置のためのタンパク質キナーゼｃ阻害剤 |
| RU2266906C1 (ru) | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
| ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| WO2005113526A2 (en) | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one |
| WO2006063709A1 (en) * | 2004-12-15 | 2006-06-22 | F.Hoffmann-La Roche Ag | Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease |
| CA2593266A1 (en) | 2005-01-03 | 2006-07-13 | Universita Degli Studi Di Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
| US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| MX2008000585A (es) | 2005-07-14 | 2008-03-14 | Hoffmann La Roche | Derivados de indol-3-il-espiro-piperidina como antagonistas del receptor v1a. |
| EP1926724A1 (en) | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| JP2007137810A (ja) * | 2005-11-17 | 2007-06-07 | Sankyo Co Ltd | インドール化合物を含有する医薬 |
| JP2009518351A (ja) | 2005-12-09 | 2009-05-07 | エフ．ホフマン−ラ ロシュ アーゲー | 肥満症の処置に有用な三環性アミド誘導体 |
| US7351706B2 (en) | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| FR2897061B1 (fr) | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| CA2683557C (en) | 2007-04-09 | 2016-10-18 | Methylgene Inc. | Inhibitors of histone deacetylase |
| JP2010531364A (ja) | 2007-06-25 | 2010-09-24 | ニューロジェン・コーポレーション | ピペラジニルオキソアルキルテトラヒドロ−β−カルボリンおよび関連類似体 |
| EP2205085A1 (en) | 2007-09-25 | 2010-07-14 | Merck Sharp & Dohme Corp. | 2-aryl or heteroaryl indole derivatives |
| CN101456863B (zh) * | 2007-12-14 | 2012-04-25 | 华北制药集团新药研究开发有限责任公司 | Lxr激动剂及其制备方法和用途 |
| CN101952293A (zh) * | 2007-12-21 | 2011-01-19 | 惠氏有限责任公司 | 吡唑并[1,5-a]嘧啶化合物 |
| TW200936591A (en) | 2008-01-22 | 2009-09-01 | Takeda Pharmaceutical | Tricyclic compounds and use thereof |
| WO2009097515A2 (en) | 2008-01-30 | 2009-08-06 | Wyeth | [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| EP2254886B1 (en) | 2008-03-28 | 2016-05-25 | Nerviano Medical Sciences S.r.l. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| TW201031665A (en) | 2009-02-04 | 2010-09-01 | Gruenenthal Gmbh | Substituted indole-compound |
| MX2011012993A (es) | 2009-06-08 | 2011-12-16 | Gruenenthal Gmbh | Bencimidazoles, benzotiazoles y benzoxazoles, sustituidos. |
| WO2011005295A1 (en) | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| MX2012002898A (es) | 2009-09-11 | 2012-04-02 | Sunovion Pharmaceuticals Inc | Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos. |
| US9073926B2 (en) | 2009-12-07 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core |
| WO2011109237A2 (en) | 2010-03-02 | 2011-09-09 | Emory University | Uses of noscapine and derivatives in subjects diagnosed with fap |
| US8654867B2 (en) * | 2011-12-07 | 2014-02-18 | Texas Instruments Incorporated | Transformer power combiner with filter response |
| ES2607113T3 (es) * | 2012-03-16 | 2017-03-29 | Vitae Pharmaceuticals, Inc. | Moduladores de los receptores X del hígado |
| SI2825541T1 (sl) * | 2012-03-16 | 2016-10-28 | Vitae Pharmaceuticals, Inc. | Modulatorji jetrnega receptorja X |
-
2013
- 2013-03-14 SI SI201330303A patent/SI2825541T1/sl unknown
- 2013-03-14 SG SG11201405328SA patent/SG11201405328SA/en unknown
- 2013-03-14 DK DK13712102.6T patent/DK2825541T3/en active
- 2013-03-14 MX MX2014011103A patent/MX354818B/es active IP Right Grant
- 2013-03-14 JP JP2015500602A patent/JP6114814B2/ja not_active Expired - Fee Related
- 2013-03-14 HU HUE13712102A patent/HUE029402T2/en unknown
- 2013-03-14 HR HRP20161196TT patent/HRP20161196T1/hr unknown
- 2013-03-14 RS RS20160785A patent/RS55166B1/sr unknown
- 2013-03-14 ES ES13712102.6T patent/ES2598653T3/es active Active
- 2013-03-14 LT LTEP13712102.6T patent/LT2825541T/lt unknown
- 2013-03-14 KR KR1020147028754A patent/KR102069912B1/ko not_active Expired - Fee Related
- 2013-03-14 PT PT137121026T patent/PT2825541T/pt unknown
- 2013-03-14 EP EP13712102.6A patent/EP2825541B1/en active Active
- 2013-03-14 NZ NZ629122A patent/NZ629122A/en not_active IP Right Cessation
- 2013-03-14 IN IN7636DEN2014 patent/IN2014DN07636A/en unknown
- 2013-03-14 CA CA2866218A patent/CA2866218C/en not_active Expired - Fee Related
- 2013-03-14 US US14/385,688 patent/US9006244B2/en active Active
- 2013-03-14 ME MEP-2016-211A patent/ME02534B/me unknown
- 2013-03-14 WO PCT/US2013/031242 patent/WO2013138565A1/en not_active Ceased
- 2013-03-14 EA EA201491609A patent/EA026907B1/ru unknown
- 2013-03-14 CN CN201380014354.5A patent/CN104203951B/zh not_active Expired - Fee Related
- 2013-03-14 PL PL13712102.6T patent/PL2825541T3/pl unknown
- 2013-03-14 AU AU2013232066A patent/AU2013232066B2/en not_active Ceased
-
2014
- 2014-08-24 IL IL234265A patent/IL234265B/en active IP Right Grant
- 2014-08-27 ZA ZA201406326A patent/ZA201406326B/en unknown
- 2014-11-19 US US14/547,804 patent/US9006245B2/en active Active
-
2015
- 2015-03-13 US US14/657,179 patent/US9388190B2/en active Active
-
2016
- 2016-06-15 US US15/182,749 patent/US9814715B2/en active Active
- 2016-09-22 CY CY20161100948T patent/CY1118318T1/el unknown
- 2016-10-14 SM SM201600374T patent/SMT201600374B/it unknown
-
2017
- 2017-03-14 JP JP2017048432A patent/JP2017128588A/ja active Pending
-
2018
- 2018-09-14 JP JP2018172260A patent/JP2019023196A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510892A5 (https=) | ||
| JP2015514061A5 (https=) | ||
| ME02660B (me) | Modulator! jetrenog x receptora | |
| HRP20161196T1 (hr) | Modulatori jetrenog receptora x | |
| JP2020519654A5 (https=) | ||
| RU2017121588A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| JP2015517579A5 (https=) | ||
| JP2014507455A5 (https=) | ||
| HRP20171258T1 (hr) | Acilamino-supstituirani kondenzirani derivati ciklopentankarboksilne kiseline i njihova upotreba kao farmaceutski proizvodi | |
| JP2017531688A5 (https=) | ||
| ME01982B (me) | 2-anilinobenzimidazol-6-karboksamidi kao anti-inflamatorni agensi | |
| HK1214968A1 (zh) | 用於非酒精性脂肪肝病(nafld)的新组合物 | |
| JP2014514322A5 (https=) | ||
| JP2013542261A5 (https=) | ||
| JP2014511891A5 (https=) | ||
| JP2013525444A5 (https=) | ||
| ME02685B (me) | Kristalni oblik pemirolasta | |
| JP2016506369A5 (https=) | ||
| JP2017537937A5 (https=) | ||
| ME02175B (me) | L-prolin i ko-kristali limunske kiseline od (2s, 3r, 4r, 5s, 6r)-2-(3- ((5- (4- fluorofenil) tiofen-2-il) metil)-4-metilfenil)-6- (hidroksimetil)tetrahidr0- 2h-piran- 3,4,s-triola | |
| JP2014520809A5 (https=) | ||
| JP2014516033A5 (https=) | ||
| JP2016532669A5 (https=) | ||
| JP2013523623A5 (https=) | ||
| JP2017505785A5 (https=) |